Venous Thromboembolism after Hospital Discharge: Temporal Trends in Baseline Characteristics, Prevention, Treatment, and 90-day Outcomes

Abstract

Venous thromboembolism (VTE) after hospital discharge poses a serious health risk. Assessments of patient characteristics, prophylaxis, treatment, outcomes, and over time changes lack consistency. Data on 16,901 hospitalized patients in the Registro Informatizado Enfermedad TromboEmbolica registry (2003–2022) were analyzed to evaluate trends in baseline characteristics, prophylaxis, treatments, and 90-day outcomes among medical (6,218) and surgical (10,683) patient cohorts. Multivariable logistic regression was used to assess the risks of the composite of fatal pulmonary embolism (PE) or recurrent VTE and major bleeding. The proportion of patients who presented with PE increased among medical (from 54 to 72%) and surgical patients (from 55 to 58%). Prophylaxis use increased in medical patients (from 53 to 71%), while decreasing in surgical patients (from 67 to 58%). Notably, the 90-day composite of fatal PE or recurrent VTE decreased in medical (from 3.9 to 1.8%) and surgical patients (from 2.9 to 1.2%; p < 0.001 for both). Conversely, major bleeding increased (3.1 to 4.5%) in medical patients (p = 0.008), with no change in surgical patients (from 2.5 to 2.4%). Risk-adjusted analysis showed a yearly decrease in the risk for the composite outcome (subhazard ratio [sHR]: 0.95; 95% confidence interval [CI]: 0.93–0.98) in medical and surgical patients and an increase in the risk for major bleeding in medical patients only (sHR: 1.04; 95% CI: 1.01–1.07). Results were consistent after excluding coronavirus disease 2019 patients. Over 20 years, the composite of fatal PE or recurrent VTE within 90 days had significantly decreased in VTE patients after hospitalization for medical or surgical care. Medical patients, however, exhibited an increase in major bleeding.

Keywords

hospital-acquired VTE - medical patients - surgical patients - anticoagulation - bleeding

Authors' Contributions

B.B., I.T., B.B., and M.M. conceived and designed the study. B.B., I.T., B.B., R.V., G.P., R.T.M., M.L.P., J.P.E., M.G.P., and M.M. collected and/or interpreted the data. All authors revised the manuscript critically for important intellectual content and gave final approval of the manuscript submitted.

^* A full list of the RIETE investigators is given in the [Appendix], available in online version only.

Publikationsverlauf

Artikel online veröffentlicht:
17. Oktober 2024

• References

• 1 Cohen AT, Tapson VF, Bergmann JF. et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371 (9610): 387-394
• 2 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
• 3 Forgo G, Micieli E, Ageno W. et al. An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. J Thromb Haemost 2022; 20 (02) 409-421
• 4 Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet 2021; 398 (10294): 64-77
• 5 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
• 6 Spyropoulos AC, Ageno W, Cohen AT, Gibson CM, Goldhaber SZ, Raskob G. Prevention of venous thromboembolism in hospitalized medically ill patients: a U.S. perspective. Thromb Haemost 2020; 120 (06) 924-936
• 7 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
• 8 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 9 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
• 10 López-Jiménez L, Montero M, González-Fajardo JA. et al; RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91 (08) 1046-1051
• 11 Bergman S, Martelli V, Monette M. et al. Identification of quality of care deficiencies in elderly surgical patients by measuring adherence to process-based quality indicators. J Am Coll Surg 2013; 217 (05) 858-866
• 12 Brenner B, Hull R, Arya R. et al. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thromb J 2019; 17: 6
• 13 Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE. European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 2016; 115 (04) 800-808
• 14 Bikdeli B, Zahedi Tajrishi F, Sadeghipour P. et al. Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review. JAMA Cardiol 2022; 7 (07) 747-759
• 15 Neeman E, Liu V, Mishra P. et al. Trends and risk factors for venous thromboembolism among hospitalized medical patients. JAMA Netw Open 2022; 5 (11) e2240373
• 16 Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med 2013; 126 (09) 832.e13-832.e21
• 17 Bikdeli B, Wang Y, Jimenez D. et al. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999-2015. JAMA 2019; 322 (06) 574-576
• 18 Barco S, Valerio L, Ageno W. et al. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respir Med 2021; 9 (01) 33-42
• 19 Bikdeli B, Jimenez D, Hawkins M. et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
• 20 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
• 21 Wells PS, Ihaddadene R, Reilly A, Forgie MA. Diagnosis of venous thromboembolism: 20 years of progress. Ann Intern Med 2018; 168 (02) 131-140
• 22 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23 (07) e334-e347
• 23 Gómez-Cuervo C, Rivas A, Visonà A. et al; RIETE Investigators. Predicting the risk for major bleeding in elderly patients with venous thromboembolism using the Charlson Index. Findings from the RIETE. J Thromb Thrombolysis 2021; 51 (04) 1017-1025
• 24 Nieto JA, Solano R, Ruiz-Ribó MD. et al; Riete Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8 (06) 1216-1222
• 25 Lecumberri R, Jiménez L, Ruiz-Artacho P. et al; RIETE investigators. Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED Scores. TH Open 2021; 5 (03) e319-e328
• 26 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
• 27 Piovella C, Dalla Valle F, Trujillo-Santos J. et al; RIETE Investigators. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. Intern Emerg Med 2014; 9 (08) 847-852
• 28 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222